Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alterity Therapeutics Ltd ADR (ATHE)

Alterity Therapeutics Ltd ADR (ATHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,556
  • Shares Outstanding, K 4,671
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,290 K
  • 60-Month Beta 0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.87
Trade ATHE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.71 +32.16%
on 03/26/24
3.19 -29.15%
on 04/12/24
+0.55 (+32.16%)
since 03/25/24
3-Month
1.55 +45.81%
on 02/23/24
3.19 -29.15%
on 04/12/24
+0.25 (+12.45%)
since 01/25/24
52-Week
1.55 +45.81%
on 02/23/24
5.41 -58.23%
on 12/04/23
-0.57 (-20.26%)
since 04/25/23

Most Recent Stories

More News
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 2.33 (+3.00%)
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?

Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.

VIR : 7.84 (+2.75%)
ATHE : 2.33 (+3.00%)
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 2.33 (+3.00%)
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

/PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease...

ATHE : 2.33 (+3.00%)
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 2.33 (+3.00%)
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 2.33 (+3.00%)
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 2.33 (+3.00%)
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 2.33 (+3.00%)
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 2.33 (+3.00%)
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 2.33 (+3.00%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses....

See More

Key Turning Points

3rd Resistance Point 2.61
2nd Resistance Point 2.54
1st Resistance Point 2.40
Last Price 2.33
1st Support Level 2.19
2nd Support Level 2.12
3rd Support Level 1.98

See More

52-Week High 5.41
Fibonacci 61.8% 3.94
Fibonacci 50% 3.48
Fibonacci 38.2% 3.02
Last Price 2.33
52-Week Low 1.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar